The Target for Statins, HMG-CoA Reductase, Is Expressed in Ductal Carcinoma-In Situ and May Predict Patient Response to Radiotherapy.
(2014) In Annals of Surgical Oncology 21(9). p.2911-2919- Abstract
- Patients with ductal carcinoma-in-situ (DCIS) are currently not prescribed adjuvant systemic treatment after surgery and radiotherapy. Prediction of DCIS patients who would benefit from radiotherapy is warranted. Statins have been suggested to exert radio-sensitizing effects. The target for cholesterol-lowering statins is HMG-CoA reductase (HMGCR), the rate-limiting enzyme in the mevalonate pathway. The aim of this study was to examine HMGCR expression in DCIS and study its treatment predictive value.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4429338
- author
- Butt, Salma LU ; Butt, Talha LU ; Jirström, Karin LU ; Werner Hartman, Linda LU ; Amini, Rose-Marie ; Zhou, Wenjing ; Wärnberg, Fredrik and Borgquist, Signe LU
- organization
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Annals of Surgical Oncology
- volume
- 21
- issue
- 9
- pages
- 2911 - 2919
- publisher
- Springer
- external identifiers
-
- pmid:24777857
- wos:000342143100017
- scopus:84906261489
- pmid:24777857
- ISSN
- 1534-4681
- DOI
- 10.1245/s10434-014-3708-4
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Cancer Epidemiology (013007100), Pathology, (Lund) (013030000), Oncology, MV (013035000), Surgery Research Unit (013242220)
- id
- 6729697b-757d-43ce-9363-1f5df1d8dd9c (old id 4429338)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/24777857?dopt=Abstract
- date added to LUP
- 2016-04-01 10:53:39
- date last changed
- 2024-01-07 03:49:58
@article{6729697b-757d-43ce-9363-1f5df1d8dd9c, abstract = {{Patients with ductal carcinoma-in-situ (DCIS) are currently not prescribed adjuvant systemic treatment after surgery and radiotherapy. Prediction of DCIS patients who would benefit from radiotherapy is warranted. Statins have been suggested to exert radio-sensitizing effects. The target for cholesterol-lowering statins is HMG-CoA reductase (HMGCR), the rate-limiting enzyme in the mevalonate pathway. The aim of this study was to examine HMGCR expression in DCIS and study its treatment predictive value.}}, author = {{Butt, Salma and Butt, Talha and Jirström, Karin and Werner Hartman, Linda and Amini, Rose-Marie and Zhou, Wenjing and Wärnberg, Fredrik and Borgquist, Signe}}, issn = {{1534-4681}}, language = {{eng}}, number = {{9}}, pages = {{2911--2919}}, publisher = {{Springer}}, series = {{Annals of Surgical Oncology}}, title = {{The Target for Statins, HMG-CoA Reductase, Is Expressed in Ductal Carcinoma-In Situ and May Predict Patient Response to Radiotherapy.}}, url = {{http://dx.doi.org/10.1245/s10434-014-3708-4}}, doi = {{10.1245/s10434-014-3708-4}}, volume = {{21}}, year = {{2014}}, }